Empagliflozin Tested in Real-World Data

Investigators assess whether EMPA-REG findings extend to broader patients with type 2 diabetes.

Share

1

Empagliflozin reduces all-cause mortality in type 2 diabetes.
2

Compared to DPP-4 inhibitors, empagliflozin shows significant mortality benefits.
3

Study used data from 62,503 adults, spanning from 2014 to
4

Majority (83%) of empagliflozin patients did not meet EMPA-REG trial criteria.
5

Adjusted hazard ratio for decreased mortality with empagliflozin is 0.
6

Findings confirm real-world efficacy of empagliflozin.
7

Study emphasizes observational research methods to corroborate randomized trial results.